DAI Xiaomin, JIANG Lindi. Practice and Application of Four-topics Theory in Decision-making of Treatment Strategies in Patients with Rheumatic Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(4): 589-593. doi: 10.12290/xhyxzz.20200171
Citation:
DAI Xiaomin, JIANG Lindi. Practice and Application of Four-topics Theory in Decision-making of Treatment Strategies in Patients with Rheumatic Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(4): 589-593. doi: 10.12290/xhyxzz.20200171
DAI Xiaomin, JIANG Lindi. Practice and Application of Four-topics Theory in Decision-making of Treatment Strategies in Patients with Rheumatic Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(4): 589-593. doi: 10.12290/xhyxzz.20200171
Citation:
DAI Xiaomin, JIANG Lindi. Practice and Application of Four-topics Theory in Decision-making of Treatment Strategies in Patients with Rheumatic Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(4): 589-593. doi: 10.12290/xhyxzz.20200171
From the perspective of clinical ethics, this article aimed to identify ethical issues and explore resolutions during decision-making process of treatment strategies in patients with rheumatic diseases. We elaborated the topics of medical indications, preference of patients, quality of life, and contextual features by using the model of "four-topics theory". Its application helped to identify and refine ethical issues, search and explore medical evidence, listen to the voice of patients, and finally promote the doctor-patient mutual participation and shared decision-making.
Jonsen AR, Siegler M, Winslade WJ. Clinical ethics: a practical approach to ethical decisions in clinical medicine[M]. 8th ed. New York: McGraw-Hill Education, 2015.
[4]
Shaban A, Leira EC. Neurological Complications in Patients with Systemic Lupus Erythematosus[J]. Curr Neurol Neurosci Rep, 2019, 19: 97. doi: 10.1007/s11910-019-1012-1
[5]
Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs[J]. Ann Rheum Dis, 2010, 69: 2074-2082. doi: 10.1136/ard.2010.130476
[6]
Ruiz-Arruza I, Lozano J, Cabezas-Rodriguez I, et al. Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long-Term Disease Control: An Observational Study[J]. Arthritis Care Res(Hoboken), 2018, 70: 582-591. doi: 10.1002/acr.23322
[7]
Legge A, Doucette S, Hanly JG. Predictors of Organ Damage Progression and Effect on Health-related Quality of Life in Systemic Lupus Erythematosus[J]. J Rheumatol, 2016, 43: 1050-1056. doi: 10.3899/jrheum.150985
[8]
Dubovsky AN, Arvikar S, Stern TA, et al. The neuropsychiatric complications of glucocorticoid use: steroid psychosis revisited[J]. Psychosomatics, 2012, 53: 103-115. doi: 10.1016/j.psym.2011.12.007